Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy
- PMID: 21531515
- DOI: 10.1016/j.ijrobp.2011.02.023
Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy
Abstract
Purpose: The optimal management of oral cavity squamous cell carcinoma (OCSCC) typically involves surgical resection followed by adjuvant radiotherapy or chemoradiotherapy (CRT) in the setting of adverse pathologic features. Intensity-modulated radiation therapy (IMRT) is frequently used to treat oral cavity cancers, but published IMRT outcomes specific to this disease site are sparse. We report the Dana-Farber Cancer Institute experience with IMRT-based treatment for OCSCC.
Methods and materials: Retrospective study of all patients treated at Dana-Farber Cancer Institute for OCSCC with adjuvant or definitive IMRT between August 2004 and December 2009. The American Joint Committee on Cancer disease stage criteria distribution of this cohort included 5 patients (12%) with stage I; 10 patients (24%) with stage II (n = 10, 24%); 14 patients (33%) with stage III (n = 14, 33%); and 13 patients (31%) with stage IV. The primary endpoint was overall survival (OS); secondary endpoints were locoregional control (LRC) and acute and chronic toxicity.
Results: Forty-two patients with OCSCC were included, 30 of whom were initially treated with surgical resection. Twenty-three (77%) of 30 surgical patients treated with adjuvant IMRT also received concurrent chemotherapy, and 9 of 12 (75%) patients treated definitively without surgery were treated with CRT or induction chemotherapy and CRT. With a median follow-up of 2.1 years (interquartile range, 1.1-3.1 years) for all patients, the 2-year actuarial rates of OS and LRC following adjuvant IMRT were 85% and 91%, respectively, and the comparable results for definitive IMRT were 63% and 64% for OS and LRC, respectively. Only 1 patient developed symptomatic osteoradionecrosis, and among patients without evidence of disease, 35% experienced grade 2 to 3 late dysphagia, with only 1 patient who was continuously gastrostomy-dependent.
Conclusions: In this single-institution series, postoperative IMRT was associated with promising LRC, OS, and lower late toxicity rates, and chemoradiotherapy was a successful treatment for patients with high-risk disease. In contrast, outcomes of radiation-based treatment for patients with inoperable locally advanced disease were markedly less successful.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.Cancer. 2010 Oct 15;116(20):4761-8. doi: 10.1002/cncr.25305. Cancer. 2010. PMID: 20572036
-
Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):308-14. doi: 10.1016/j.ijrobp.2010.09.042. Epub 2010 Nov 13. Int J Radiat Oncol Biol Phys. 2012. PMID: 21075557
-
Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1096-103. doi: 10.1016/j.ijrobp.2008.05.024. Epub 2008 Aug 15. Int J Radiat Oncol Biol Phys. 2009. PMID: 18707827
-
Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients.Cancer. 2005 Jul 1;104(1):71-82. doi: 10.1002/cncr.21100. Cancer. 2005. PMID: 15915466 Review.
-
Intensity-Modulated Radiation Therapy for Early-Stage Squamous Cell Carcinoma of the Glottic Larynx: A Systematic Review and Meta-Analysis.Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):652-663. doi: 10.1016/j.ijrobp.2023.04.035. Epub 2023 May 6. Int J Radiat Oncol Biol Phys. 2023. PMID: 37150263 Free PMC article.
Cited by
-
Dose coverage comparison between "interstitial catheter-only" and "hybrid intracavitary-interstitial brachytherapy" for early stage squamous cell carcinoma of the buccal mucosa.J Contemp Brachytherapy. 2018 Oct;10(5):486-491. doi: 10.5114/jcb.2018.79471. Epub 2018 Oct 31. J Contemp Brachytherapy. 2018. PMID: 30479628 Free PMC article.
-
Contemporary Treatment of Locally Advanced Oral Cancer.Curr Treat Options Oncol. 2019 Mar 14;20(4):32. doi: 10.1007/s11864-019-0631-8. Curr Treat Options Oncol. 2019. PMID: 30874958 Review.
-
Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers.Head Neck. 2015 Nov;37(11):1633-41. doi: 10.1002/hed.23806. Epub 2014 Aug 28. Head Neck. 2015. PMID: 24954094 Free PMC article.
-
Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis.JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):691-699. doi: 10.1001/jamaoto.2017.0012. JAMA Otolaryngol Head Neck Surg. 2017. PMID: 28426848 Free PMC article.
-
Clinical effectiveness, toxicity, and failure patterns of helical tomotherapy for postoperative oral cavity cancer patients.Onco Targets Ther. 2014 Mar 10;7:405-14. doi: 10.2147/OTT.S59998. eCollection 2014. Onco Targets Ther. 2014. PMID: 24648744 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous